| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Psychiatry and Behavioural Neurosciences (Drs. Rosebush and Mazurek) and the Department of Medicine (Neurology) (Dr. Mazurek), McMaster University Medical Centre, Hamilton, Ontario, Canada.
Address correspondence and reprint requests to Dr. Patricia I. Rosebush, Department of Psychiatry and Behavioural Neurosciences, McMaster University Medical Centre, Room 3G15, 1200 Main West, Hamilton, Ontario, Canada L8N 3Z5.
OBJECTIVE: To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs).
BACKGROUND: Early studies suggested that the APD risperidone may have a side effect profile comparable with that of placebo. These early studies involved patients with chronic schizophrenia and a long history of APD use. Very little information is available regarding the neurologic side effects of risperidone in patients without previous APD exposure.
METHODS: The authors prospectively studied 350 consecutive neuroleptic-naive patients admitted to their acute-care psychiatry service; 34 of these were treated with risperidone (mean dose, 3.2 mg/d) and 212 were treated with low-dose haloperidol (mean dose 3.7 mg/d). All patients were assessed on admission and twice weekly thereafter using rating scales for dystonia, parkinsonism, akathisia, and dyskinesia.
RESULTS: The incidence and severity of dystonic reactions, akathisia, parkinsonism, and dyskinesia were comparable in the risperidone- and haloperidol-treated groups.
CONCLUSIONS: The neurologic side effect profile of low-dose risperidone is comparable with that of haloperidol in patients receiving APDs for the first time. Risperidone may not be a useful alternative to typical APDs for patients with PD and psychosis.
This article has been cited by other articles:
|
|
 |
|
  D. C. Owens How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Advan. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]
|
|
|
|
 |
|
 A E Hensiek and M R Trimble Relevance of new psychotropic drugs for the neurologist J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 281 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Windhaber, S. Urbanits, W. Grisold, M. F. Mazurek, and P. I. Rosebush Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone Neurology, April 11, 2000; 54(7): 1542 - 1546. [Full Text] [PDF]
|
|
|
|
 |
|
 P. I. Rosebush, S. Garside, A. J. Levinson, and M. F. Mazurek The Neuropsychiatry of Adult-Onset Adrenoleukodystrophy J Neuropsychiatry Clin Neurosci, August 1, 1999; 11(3): 315 - 327. [Abstract] [Full Text]
|
|
|
|
 |
|
 No Side Effect Benefits with Risperidone in Drug-Naive Patients . . . Journal Watch Psychiatry, May 1, 1999; 1999(501): 6 - 6. [Full Text]
|
|
|
|
 |
|
 Side Effects of Risperidone vs. Haloperidol Journal Watch (General), March 26, 1999; 1999(326): 7 - 7. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
